fulvestrant has been researched along with Overweight in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N | 1 |
| Lindman, H; Valachis, A; Zewenghiel, L | 1 |
1 trial(s) available for fulvestrant and Overweight
| Article | Year |
|---|---|
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss | 2021 |
1 other study(ies) available for fulvestrant and Overweight
| Article | Year |
|---|---|
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Obesity; Overweight; Postmenopause; Retrospective Studies; Sweden; Treatment Outcome | 2018 |